Elite Health Systems Inc.
For the period ended Dec 31, 2024. Filed Apr 2, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 2, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 11. Executive Compensation
The information below sets forth the compensation for the years ended December 31, 2024, 2023, and 2022 for the President of the Company.
| Summary Compensation Table | ||
|---|---|---|
| Name and | Annual Compensation | |
| Principal Position | Year | Salary |
| Alan Gold | 2024 | $25,000 |
| President & Chairman of the Board | 2023 | $125,000 |
| 2022 | $188,000 | |
Employee Benefits; Employment Agreement
Mr. Gold was entitled to reimbursement of up to $1,000 per month for automobile expenses, which arrangement ceased in September 2023. In addition, Mr. Gold was entitled to participate in the Company’s health and life insurance program until that benefit was terminated in February 2024. The Company also paid the premiums in 2023 for a life insurance policy on Mr. Gold in the amount of $500,000, naming Mr. Gold’s wife as beneficiary. On July 10, 2024, Mr. Gold resigned from his position as President of the Company, effective immediately. Mr. Gold continues to serve as a member of the Board, but as of the effective date no longer serves as the Chairman of the Board.
Director Compensation
Through March 31, 2023, our directors, who are not officers or employees, were paid a monthly retainer of $3,000. Monthly payments were reduced to $2,000 beginning in April 2023. Mr. Leimkuhler received aggregate cash payments of $31,000 in 2023. During 2023, Mr. St. Lawrence received aggregate cash payments of $12,000 and a grant of 50,000 shares of the Company’s Common Stock, which had a per share fair market value of approximately $4,500 at the time of grant. Mr. Merriman declined compensation for serving as a director during 2023. Directors of the Company who are officers or employees do not receive any additional compensation for serving on the Board. In January 2025 the Board issued 75,000 restricted shares to each of Messrs. St. Lawrence and Leimkuhler with an approximate value of $37,500 in lieu of cash compensation for the year ended December 2024. Similarly, Dr. Jeereddi and BaoBao Reheer was granted 250,000 and 75,000 shares of stock, respectively, as compensation for serving as CEO and chairman of the board and Executive Director of the Company for the year ended December 31,2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.